1.4 Hepatic Biotransformation, Phase I/II Reactions, and CYP450 Interactions

Lipophilic xenobiotics readily cross biological membranes and would undergo near-complete passive reabsorption across renal tubular epithelium, persisting indefinitely in the body without enzymatic biotransformation. Hepatic biotransformation converts lipophilic chemicals into polar, water-soluble, ionized metabolites that can be excreted in bile and urine.

Biotransformation proceeds through two sequential enzyme phases:

1. Phase I Reactions (Functionalization): Introduces or unmasks a polar functional group (-OH, -NH₂, -SH, or -COOH) via oxidation, reduction, or hydrolysis.
2. Phase II Reactions (Conjugation): Covalently couples an endogenous, highly water-soluble polar moiety (glucuronic acid, sulfate, glutathione, acetate, or amino acids) to the functional group.

Lipophilic Xenobiotic → [Phase I: CYP450] → Functionalized Intermediate → [Phase II: Transferase] → Hydrophilic Conjugate → Excretion
                                              ↓ (Overdose / Saturation)
                                     Reactive Toxic Metabolite (NAPQI, Epoxides)

---

Phase I Biotransformation: The Cytochrome P450 Superfamily

The Cytochrome P450 (CYP) superfamily consists of membrane-bound, heme-thiolate monooxygenases localized predominantly within the smooth endoplasmic reticulum of hepatocytes and enterocytes. The canonical monooxygenase reaction requires molecular oxygen, NADPH, and the electron-transfer protein NADPH-cytochrome P450 reductase:

$\text{RH} + \text{O}_2 + \text{NADPH} + \text{H}^+ \xrightarrow{\text{CYP}} \text{ROH} + \text{H}_2\text{O} + \text{NADP}^+$

Six specific CYP isoenzymes account for more than 90% of all clinically significant drug biotransformation:

1. CYP3A4/5

• Significance: The most abundant CYP enzyme in humans, comprising ~30% of hepatic CYP content and ~70% of intestinal mucosal CYP. Metabolizes over 50% of prescription pharmaceuticals.
• Key Substrates: Calcium channel blockers (amlodipine, diltiazem, verapamil), statins (simvastatin, atorvastatin), fentanyl, methadone, midazolam, carbamazepine, quetiapine, cyclosporine, colchicine.
• Potent Inducers: Rifampin, carbamazepine, phenytoin, phenobarbital, and St. John's wort (via pregnane X receptor [PXR] activation).
• Potent Inhibitors: Ketoconazole, itraconazole, clarithromycin, erythromycin, ritonavir, cobicistat, diltiazem, and grapefruit juice (furanocoumarins like bergamottin, which selectively and irreversibly destroy intestinal mucosal CYP3A4).
• Toxicological High-Yield Risk: Co-administration of a potent CYP3A4 inhibitor with colchicine blocks colchicine elimination, triggering multi-organ failure, bone marrow aplasia, and death. Co-ingestion with simvastatin causes massive rhabdomyolysis.

2. CYP2D6

• Significance: Accounts for only ~2% of total hepatic CYP content, yet metabolizes 20–25% of therapeutic drugs. Highly polymorphic; cannot be clinically induced by environmental xenobiotics.
• Key Substrates: Tricyclic antidepressants (amitriptyline, nortriptyline), beta-blockers (metoprolol, carvedilol), venlafaxine, haloperidol, dextromethorphan, and opioids (codeine and tramadol, which are prodrugs, plus hydrocodone and oxycodone, which form more potent metabolites).
• Potent Inhibitors: Fluoxetine, paroxetine, bupropion, quinidine.
• Toxicological High-Yield Risk: Fluoxetine or bupropion added to a stable regimen of codeine blocks conversion to morphine, eliminating analgesia. Conversely, inhibition of TCA metabolism produces lethal cardiotoxicity.

3. CYP2C9

• Significance: Primary clearance pathway for narrow-therapeutic-index acidic drugs.
• Key Substrates: S-warfarin (the clinically potent enantiomer), phenytoin, sulfonylureas (glipizide, glyburide).
• Potent Inhibitors: Fluconazole, amiodarone, sulfamethoxazole-trimethoprim (Bactrim), metronidazole.
• Toxicological High-Yield Risk: Initiating a course of fluconazole or Bactrim in a patient on stable warfarin arrests S-warfarin clearance, producing severe coagulopathy (INR >10) and life-threatening hemorrhage within 3 to 5 days. Added to glipizide, it triggers refractory hypoglycemia.

4. CYP2C19

• Significance: Critical for the bioactivation of thienopyridine antiplatelet prodrugs.
• Key Substrates: Clopidogrel, diazepam, omeprazole, citalopram, voriconazole.
• Potent Inhibitors: Omeprazole, fluvoxamine, ticlopidine.
• Toxicological High-Yield Risk: Clopidogrel requires two-step hepatic CYP activation; poor metabolizers or patients taking strong inhibitors fail to form the active platelet-inhibiting thiol metabolite, risking acute stent thrombosis.

5. CYP1A2

• Significance: Constitutively expressed in liver; uniquely induced by polycyclic aromatic hydrocarbons.
• Key Substrates: Theophylline, caffeine, clozapine, olanzapine, tizanidine, acetaminophen (minor pathway).
• Potent Inducers: Tobacco smoke and cannabis smoke (polycyclic aromatic hydrocarbons activating the aryl hydrocarbon receptor [AhR]), chargrilled meats, carbamazepine, omeprazole.
• Potent Inhibitors: Ciprofloxacin, fluvoxamine.
• Toxicological High-Yield Risk: A patient stabilized on clozapine or theophylline who is prescribed ciprofloxacin experiences immediate enzyme inhibition, precipitating acute clozapine toxicity (seizures, sedation, hypotension) or theophylline toxicity (seizures, refractory tachyarrhythmias).

6. CYP2E1

• Significance: Primary catalyst for ethanol, acetone, and volatile halogenated hydrocarbons; major toxifying enzyme in acetaminophen poisoning.
• Key Substrates: Ethanol, acetaminophen, carbon tetrachloride, halothane, isoniazid.
• Inducers: Chronic ethanol consumption, isoniazid, fasting/starvation, diabetic ketosis.
• Toxicological High-Yield Risk: Chronic alcoholics have elevated hepatic CYP2E1 levels. Following acute APAP ingestion, a markedly higher proportion of acetaminophen is bioactivated into toxic NAPQI, substantially lowering the hepatotoxic threshold dose.

---

Non-CYP Phase I Enzymes

• Alcohol Dehydrogenase (ADH): Cytosolic zinc metalloenzyme that oxidizes primary alcohols to aldehydes (ethanol to acetaldehyde; methanol to formaldehyde; ethylene glycol to glycolaldehyde).
• Aldehyde Dehydrogenase (ALDH): Mitochondrial enzyme converting aldehydes to carboxylic acids (acetaldehyde to acetate; formaldehyde to formic acid; glycolaldehyde to glycolic acid). Blocked by disulfiram and coprine (found in Coprinopsis atramentaria mushrooms).
• Carboxylesterases & Butyrylcholinesterase (Pseudocholinesterase): Plasma and tissue esterases that rapidly hydrolyze ester-containing xenobiotics, including cocaine, heroin, succinylcholine, and local anesthetics.

---

Phase II Conjugation Pathways

Phase II enzymes attach hydrophilic endogenous co-substrates to polar chemical handles, almost always terminating biological activity and facilitating rapid biliary or urinary excretion.

---

Enzyme Induction vs. Inhibition Dynamics

Enzyme Induction:  Nuclear Receptors (PXR/CAR/AhR) → Gene Transcription → New Protein Synthesis (Days to Weeks)
Enzyme Inhibition: Direct Competitive / Mechanism-Based Binding to Active Site → Immediate Arrest (Hours)

Pharmacokinetics of Induction

Induction is not an acute, instantaneous event. Xenobiotics bind to cytoplasmic/nuclear receptors—such as the Pregnane X Receptor (PXR), Constitutive Androstane Receptor (CAR), or Aryl Hydrocarbon Receptor (AhR). The ligand-receptor complex translocates to the nucleus, heterodimerizes with the Retinoid X Receptor (RXR), and binds response elements in the promoter region of CYP genes, up-regulating mRNA transcription and de novo enzyme synthesis.

• Time Course: Requires 7 to 14 days of continuous exposure to reach maximal enzyme capacity.
• Offset: Persists for 1 to 3 weeks after the inducing agent is discontinued, while the excess enzyme pool degrades.

Pharmacokinetics of Inhibition

Inhibition occurs immediately upon the inhibitor reaching the enzyme site:

• Competitive Inhibition: Reversible; the inhibitor competes directly with substrate for the catalytic binding pocket. Onset is immediate, resolving as the inhibitor is cleared.
• Mechanism-Based ("Suicide") Inactivation: The enzyme bioactivates the inhibitor into a reactive intermediate that covalently bonds to the heme or apoprotein moiety of the enzyme, permanently destroying catalytic activity (e.g., grapefruit juice furanocoumarins inactivating intestinal CYP3A4). Restoration requires de novo enzyme synthesis.

---

Bioactivation: Generation of Toxic Metabolites

Many parent xenobiotics possess low intrinsic toxicity but are transformed by endogenous enzymes into lethal cytotoxins (bioactivation):

Methanol        ──(ADH)──>  Formaldehyde   ──(ALDH)──>  Formic Acid (Complex IV Toxin, Retinal Necrosis)
Ethylene Glycol ──(ADH)──>  Glycolaldehyde ──(ALDH)──>  Glycolic Acid (Severe Acidosis) ──> Oxalic Acid (Renal AKI)
Acetaminophen   ──(CYP)──>  NAPQI (Glutathione Depletion → Hepatocellular Centrilobular Necrosis)
Codeine         ──(2D6)──>  Morphine (Respiratory Depression; Fatal in Ultra-Rapid Metabolizers)

Toxic Alcohols and ADH Inhibition

• Methanol: Metabolized by ADH to formaldehyde, then rapidly by ALDH to formic acid. Formic acid inhibits cytochrome oxidase, causing profound anion gap metabolic acidosis, optic disc hyperemia, retinal edema, and blindness.
• Ethylene Glycol: Metabolized by ADH to glycolaldehyde, then to glycolic acid, which causes life-threatening metabolic acidosis. Glycolic acid is further converted to glyoxylic acid and oxalic acid. Oxalic acid precipitates with ionized calcium, forming insoluble calcium oxalate monohydrate crystals in renal tubules, leading to acute kidney injury, flank pain, and systemic hypocalcemia.
• Antidotal Strategy: Fomepizole (4-methylpyrazole) is a competitive inhibitor of ADH with an affinity approximately 8,000 times greater than ethanol (Ki ≈ 0.1 μM). Administering fomepizole halts toxic alcohol bioactivation immediately, allowing un-metabolized parent alcohols to be cleared safely via hemodialysis or excreted in urine.

---

Pharmacogenomics in Clinical Toxicology

Genetic polymorphisms in drug-metabolizing enzymes create dramatic disparities in patient susceptibility to toxicity:

1. N-Acetyltransferase-2 (NAT2) Polymorphism

Human populations exhibit a genetically determined bimodal distribution of NAT2 activity:

• Slow Acetylators (Homozygous Recessive): Possess reduced NAT2 activity (~50% of the Caucasian and African-American populations).
  • Isoniazid (INH) Neurotoxicity: Slow acetylators eliminate parent INH poorly. Elevated parent INH reacts with pyridoxal-5'-phosphate and inhibits pyridoxine phosphokinase, causing functional pyridoxine (vitamin B6) deficiency. Because pyridoxine is the obligate co-factor for glutamic acid decarboxylase (GAD), central synthesis of the inhibitory neurotransmitter GABA ceases, precipitating intractable status epilepticus that responds only to IV pyridoxine replacement.
  • Drug-Induced Lupus Erythematosus (DILE): Slow acetylators have a dramatically higher risk of developing DILE when treated with hydralazine or procainamide.
  • Dapsone: Slower acetylation shunts dapsone into CYP-mediated N-hydroxylation, generating toxic dapsone hydroxylamine, which causes severe methemoglobinemia and hemolysis.
• Rapid Acetylators: Clear parent INH rapidly, but generate larger quantities of monoacetylhydrazine, which can be bioactivated into hepatotoxic intermediates.

2. CYP2D6 Genetic Polymorphisms

The CYP2D6 gene is highly polymorphic, with over 100 allelic variants categorizing patients into four distinct phenotypes:

• Poor Metabolizers (PM): Carry two non-functional alleles (~7–10% of Caucasians). Cannot bioactivate prodrugs (codeine, tramadol) into active analgesics (morphine, M1); experience complete therapeutic failure.
• Intermediate Metabolizers (IM): Reduced metabolic activity.
• Normal / Extensive Metabolizers (NM/EM): Normal metabolic function.
• Ultra-Rapid Metabolizers (UM): Carry gene duplications or amplifications (up to 13 copies of the functional CYP2D6 gene), seen in up to 10–29% of North African, Ethiopian, and Arab populations.

Tragic Clinical Scenario: A nursing mother who is a CYP2D6 Ultra-Rapid Metabolizer takes standard therapeutic doses of codeine for post-partum pain. Her liver rapidly bioactivates codeine into massive concentrations of morphine, which pass into breast milk. Her breastfed infant develops severe lethargy, pinpoint pupils, apnea, and fatal morphine toxicity. Similar post-tonsillectomy pediatric deaths led to FDA contraindications for codeine and tramadol in children under 12 years of age.

3. Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency

G6PD is the rate-limiting enzyme of the hexose monophosphate shunt, the sole cellular pathway generating NADPH in mature erythrocytes. Red blood cells require NADPH to regenerate reduced glutathione (GSH), which neutralizes ambient oxidative stress.

When patients with X-linked G6PD deficiency are exposed to oxidant xenobiotics (dapsone, rasburicase, primaquine, methylene blue), erythrocytes cannot regenerate GSH. Unchecked oxidative stress oxidizes hemoglobin sulfhydryl groups and peroxidizes membranes, precipitating Heinz body formation, acute intravascular hemolysis, and hemoglobinuric renal failure.